November 22, 2022 7:44am
Indications: 1 Negative Indication, 1 Positive Indication and 1 Pump/Promote
A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.
I don’t seek fame, do podcasts or give speeches; what I do is write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth!
8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.22% or (+72 points), S&P futures are UP +0.23% or (+9 points) and NASDAQ futures are UP +0.17% or (+19 points) early in the pre-open – so far,
Stock futures rose were mixed Tuesday morning,
European markets were uneven,
Asia-Pacific markets mostly fell as Chinese cope with Covid challenges
We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …
Monday,” Indexes shillyshallied in a volatile session to start a short, holiday interrupted week due to Thanksgiving; as markets exhibited increased volatility and lower volumes into the final hour of trading as traders take time off.”
The Dow closed DOWN -44.82 points (-0.13%), the S&P close DOWN -15.35 points (-0.39%) while the Nasdaq closed DOWN -121.55 points (-1.09%)
Economic Data Docket: Philadelphia Fed’s nonmanufacturing business outlook survey and the Richmond Fed’s manufacturing index.
Monday’s (11/21) … RegMed Investors’ (RMi) closing bell: “short, holiday interrupted week; also, a vacation one for me with a shortened closing bell’ report” … https://www.regmedinvestors.com/articles/12710
Ebb and flow:
Q4 – November - 9 negative and 6 positive closes
· October -1 neutral, 11 positive and 9 negative closes
· September – 1 holiday, 10 positive and 11 negative closes
· August – 1 neutral, 11 positive and 11 negative closes
· July - 1 holiday, 10 negative and 10 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Beam Therapeutics (BEAM) closed down -$1.47 to $45.31 with a negative -$1.14 or -2.51% pre-open indication,
Ultragenyx (RARE) closed down -$1.62 to $34.37 with a positive +$1.71 or +4.98% pre-open indication.
Puff/Pump and Promote: Maintaining SELL
Biostage (OTCQB: BSTG) closed up +$0.07 with 500 shares traded after Friday’s -$0.37 to $6.13 with 802 shares traded, Thursday’s +$0.35 with 2,947 shares traded, Wednesday’s -$0.15 with 228 shares traded and last Tuesday’s -$0.60 with 2,231 shares traded <3-month average = 2,485 shares>
A DRAFT prospectus is filed … SEC Form S-1/A …https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=117017206&type=HTML&formType=S-1%2FA&dateFiled=2022-10-27&cik=0001563665&CK=1563665&symbol=0001563665&companyName=Biostage . Questions arise as to draft prospectus statement of non-reliance of past financials? Hey, CFO Joe some of us have copies of lost “payables”?
The BOTTOM LINE: I try to keep it simple … and short while repeating what I did write last night!
Reiterating from this morning, “It’s Thanksgiving Week – supposedly a week to say “thanks”.
But, to WHOM?
NO thanks …to CEO Sue Washer and president (currently) of Applied Genetic Technologies (AGTC) for her “mistakes in management and judgement” during her tenure (let’s NOT forget her “bored” of directors) – who let her get away with such “mis-judgements” to have to sell-out the company for pennies as she executes her “exit package” of $1.5+ million having been paid $1.5 million to “wreck” the company this year.
Key word, uncertainty … “which makes It difficult to predict where the cell and gene therapy sector is headed in the short run.”
Amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that … lately we are investors are safer on the sidelines.
Reiterating, “The real question that should be asked is how many companies are at the end of sentiments … leash? I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”.
Insight is about understanding perception and also about putting into context what is relevant to expectation fulfillment
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.